Unicycive Q2 net loss $4.4M; OLC FDA feedback expected Fall 2023; UNI-494 Phase 1 ongoing

Unicycive Therapeutics, Inc.

2023-Q2 EPS reported -$1.26 revenue$675,000

Net loss of $4.4M ($0.29/share) in Q2 2023, up from $3.6M ($0.24) in Q2 2022 due to higher R&D and G&A costs.
Cash and equivalents totaled $18.8M as of June 30, 2023.
Positive OLC data published in Am J Nephrol: lowest daily dose volume vs five commercial phosphate binders.
Expects FDA alignment feedback in Fall 2023 for OLC program; NDA submission after that.
UNI-494 Phase 1 trial ongoing in UK; pre-IND meeting with FDA planned by year-end; IND expected in 2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Unicycive Therapeutics, Inc. reported the second quarter ended June 30, 2023 results: net income $4.4 million, EPS $0.29 per share of common stock.

Period: the second quarter ended June 30, 2023
Net income: $4.4 million
EPS: $0.29 per share of common stock
Result: reported results

Exact text from the filing

Net loss attributable to common stockholders for the quarter ended June 30, 2023 was $4.4 million, or $0.29 per share of common stock

View on SEC.gov

168 earnings releases filed in the last 30 days. Browse all earnings releases →

Unicycive Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001213900-23-067398

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.